Key Highlights
• Protara Therapeutics (NASDAQ: TARA) confirmed the resignation of Chief Medical Officer Leonardo Viana Nicacio, effective June 26, 2026.
• Clinical oversight will be assumed by Carla Beckham, M.D. And Jacqueline Zummo, Ph.D. Chief Research & Development Officer.
• The change was disclosed in a Form 8-K filing with the U.S. Securities and Exchange Commission on June 29, 2026.
• The company has not named a successor and will manage duties through existing leadership.
Protara Therapeutics (NASDAQ: TARA) disclosed a leadership change this week, announcing the departure of its Chief Medical Officer. The biotech company filed regulatory documents detailing the transition, which becomes effective later this month.
Leadership Transition Confirmed
Protara Therapeutics reported that Leonardo Viana Nicacio, M.D. Has stepped down from his position as Chief Medical Officer. The resignation, effective June 26, 2026, was formally communicated in a filing with the U.S. Securities and Exchange Commission.
Nicacio’s departure follows his decision to explore new career opportunities outside the company.
Clinical Responsibilities Reassigned
Following Nicacio’s exit, Protara Therapeutics will reallocate clinical leadership duties among its current team. Carla Beckham, M.D. A senior member of the medical team, will take on additional responsibilities. Jacqueline Zummo, Ph.D. The company’s Chief Research & Development Officer, will maintain oversight of development activities.
The company has not indicated plans to bring in an external replacement at this stage.
Regulatory Filing Details
The company submitted the required Form 8-K filing on June 29, 2026, in compliance with U.S. Securities regulations. The document confirms the resignation and describes the internal adjustments to clinical leadership.
As with all such filings, it was signed by an authorized company representative.
Implications for Development Programs
The leadership change comes as Protara Therapeutics continues to advance its clinical programs. While the company has not suggested any immediate disruptions, the transition may draw attention from stakeholders monitoring trial progress and regulatory engagements. Beckham and Zummo will collaborate to ensure continuity in medical strategy execution.
Investor Considerations
Shares of Protara Therapeutics (NASDAQ: TARA) may experience fluctuations as investors evaluate the impact of the CMO’s departure. Leadership stability is often a key factor in biotech, where clinical progress and regulatory interactions play a critical role in company valuation. The company has not issued further statements beyond the regulatory disclosure.
Company Outlook
Protara Therapeutics has not announced a timeline for naming a permanent successor. The current approach emphasizes maintaining operational continuity while the company assesses its long-term leadership structure. Observers will likely watch for updates on clinical milestones and any strategic adjustments in the months ahead.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...